Teva Pharmaceutical Industries Limited (NYSE:TEVA) Shares Acquired by Financial Counselors Inc.

Financial Counselors Inc. lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 24.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 70,147 shares of the company’s stock after acquiring an additional 13,675 shares during the quarter. Financial Counselors Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,546,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Diversify Advisory Services LLC grew its position in Teva Pharmaceutical Industries by 2.5% during the 4th quarter. Diversify Advisory Services LLC now owns 20,355 shares of the company’s stock worth $426,000 after purchasing an additional 496 shares during the period. Sanctuary Advisors LLC grew its holdings in Teva Pharmaceutical Industries by 1.9% during the third quarter. Sanctuary Advisors LLC now owns 35,129 shares of the company’s stock worth $601,000 after acquiring an additional 664 shares during the period. Thrivent Financial for Lutherans lifted its holdings in Teva Pharmaceutical Industries by 0.3% in the fourth quarter. Thrivent Financial for Lutherans now owns 225,210 shares of the company’s stock valued at $4,964,000 after acquiring an additional 699 shares during the period. Metis Global Partners LLC boosted its position in Teva Pharmaceutical Industries by 6.7% in the 4th quarter. Metis Global Partners LLC now owns 13,697 shares of the company’s stock worth $302,000 after purchasing an additional 860 shares in the last quarter. Finally, DGS Capital Management LLC grew its stake in shares of Teva Pharmaceutical Industries by 6.8% during the 3rd quarter. DGS Capital Management LLC now owns 13,627 shares of the company’s stock worth $246,000 after purchasing an additional 872 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on TEVA shares. Piper Sandler boosted their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a research note on Friday, January 17th. StockNews.com lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday. UBS Group cut their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research note on Thursday, January 30th. Bank of America lowered their price target on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a research report on Thursday, March 6th. Finally, Barclays cut their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, January 30th. Two analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $23.43.

Teva Pharmaceutical Industries Price Performance

Shares of Teva Pharmaceutical Industries stock opened at $15.52 on Friday. The company has a debt-to-equity ratio of 2.97, a current ratio of 0.98 and a quick ratio of 0.75. The business has a 50 day simple moving average of $17.35 and a two-hundred day simple moving average of $18.14. The stock has a market capitalization of $17.60 billion, a P/E ratio of -10.71, a PEG ratio of 1.44 and a beta of 0.82. Teva Pharmaceutical Industries Limited has a 12 month low of $12.51 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.